1h Free Analyst Time
According to the recently published report 'Retinoic Acid Receptor Gamma - Drugs In Development, 2022'; Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) pipeline Target constitutes close to 16 molecules. Out of which approximately 16 molecules are developed by Companies.Speak directly to the analyst to clarify any post sales queries you may have.
Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Retinoic acid receptor gamma (RARG) is a nuclear receptor that is encoded by the RARG gene. RARG bind as heterodimers to the target response elements in response to their ligands (all-trans or 9-cis retinoic acid) and regulate gene expression in various biological processes. In the absence or presence of hormone ligand, acts mainly as an activator of gene expression due to weak binding to co-repressors. It is required for limb bud development.
The report 'Retinoic Acid Receptor Gamma - Drugs In Development, 2022' outlays comprehensive information on the Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Preclinical and Discovery stages are 2, 1, 3, 2, 7 and 1 respectively. Report covers products from therapy areas Dermatology, Musculoskeletal Disorders, Ophthalmology, Respiratory, Gastrointestinal, Immunology, Infectious Disease, Metabolic Disorders and Oncology which include indications Acne Vulgaris, Bronchopulmonary Dysplasia, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Fibrosis, Hand Dermatitis, Head And Neck Cancer, Inflammatory Bowel Disease, Kaposi Sarcoma, Keratoconjunctivitis Sicca (Dry Eye), Retinopathy Of Prematurity, Spondyloarthritis (Spondyloarthropathy), Systemic Lupus Erythematosus and Type 1 Diabetes (Juvenile Diabetes).
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG)
- The report reviews Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics and enlists all their major and minor projects
- The report assesses Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Overview
- Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Companies Involved in Therapeutics Development
- Advent Therapeutics Inc
- Avecho Biotechnology Ltd
- Bausch Health Companies Inc
- Boehringer Ingelheim International GmbH
- Galephar Pharmaceutical Research Inc
- Ipsen SA
- Lee's Pharmaceutical Holdings Ltd
- Orphanix GmbH
- Ortho Dermatologics Inc
- Promius Pharma LLC
- Sveikatal Inc
- TherapyX Inc
- Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Drug Profiles
- Product Description
- Mechanism Of Action
- History of Events
- Product Description
- Mechanism Of Action
- History of Events
- Product Description
- Mechanism Of Action
- History of Events
- Product Description
- Mechanism Of Action
- History of Events
- alitretinoin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- alitretinoin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- bexarotene + CD-1530 - Drug Profile
- Product Description
- Mechanism Of Action
- palovarotene - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Antagonize ROR-Gamma for Autoimmune Disorders, Allergies and Spondylosis - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules 1 to Agonize Retinoic Acid Receptor Gamma for Musculoskeletal Disorders - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Agonize RARG for Fibrosis - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecules to Agonize Retinoic Acid Receptor Gamma for Musculoskeletal Disorders - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- tazarotene - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- tazarotene - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- tretinoin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- tretinoin - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- trifarotene - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- vitamin A palmitate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- vitamin A palmitate - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Dormant Products
- Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Discontinued Products
- Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Product Development Milestones
- Featured News & Press Releases
- Jun 29, 2022: Ipsen announces U.S. FDA priority review for palovarotene new drug application in patients with fibrodysplasia ossificans progressiva following resubmission
- Mar 22, 2022: Ortho Dermatologics will present new data on IDP-126 Gel at the 2022 American Academy of Dermatology Annual Meeting
- Jan 24, 2022: Health Canada approves Ipsen’s Sohonos (palovarotene capsules) as the first approved treatment for Fibrodysplasia Ossificans Progressiva
- Oct 28, 2021: The first and only tazarotene lotion indicated for acne vulgaris in patients 10 years of age and older, ARAZLO now available for patients by prescription across Canada
- Oct 19, 2021: Ortho Dermatologics to present new data on ARAZLO at the 2021 Fall Clinical Dermatology Conference
- Sep 13, 2021: Voluntary announcement Adapalene Clindamycin Hydrochloride combination gel passing the on site inspection for drug registration in China becoming the third GMP inspection that the company has passed this year
- Aug 13, 2021: Ipsen announces withdrawal of palovarotene NDA, confirming intention to re-submit following additional data analyses
- Aug 04, 2021: Health Canada approves ARAZLO (Tazarotene) Lotion, 0.045%, first such lotion treatment for acne vulgaris
- May 28, 2021: Ipsen confirms U.S. FDA accepts new drug application for Palovarotene as the first potential treatment worldwide for fibrodysplasia ossificans progressiva (FOP)
- Apr 22, 2021: Ortho Dermatologics announces statistically significant topline results from second pivotal phase 3 clinical trial evaluating IDP-126 gel in acne vulgaris
- Apr 21, 2021: Ortho Dermatologics to present abstract on ARAZLO (tazarotene) Lotion at 2021 American Academy of Dermatology Annual Meeting
- Feb 24, 2021: Galderma and Aklief (trifarotene) cream, 0.005% unveil me being me campaign to inspire young people with acne to live life to the fullest
- Feb 09, 2021: Lee’s Pharmaceutical Holdings: Update on an investigational dermatology product
- Nov 16, 2020: Trifarotene in moderate acne: no study data for the assessment of the added benefit
- Sep 10, 2020: Ipsen to present new Insights at ASBMR for potential treatment of ultra-rare disease Fibrodysplasia Ossificans Progressiva (FOP), including global phase III MOVE Trial results
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indication, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Products under Development by Companies, 2022 (Contd..1)
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by Advent Therapeutics Inc, 2022
- Pipeline by Avecho Biotechnology Ltd, 2022
- Pipeline by Bausch Health Companies Inc, 2022
- Pipeline by Boehringer Ingelheim International GmbH, 2022
- Pipeline by Galephar Pharmaceutical Research Inc, 2022
- Pipeline by Ipsen SA, 2022
- Pipeline by Lee's Pharmaceutical Holdings Ltd, 2022
- Pipeline by Orphanix GmbH, 2022
- Pipeline by Ortho Dermatologics Inc, 2022
- Pipeline by Promius Pharma LLC, 2022
- Pipeline by Sveikatal Inc, 2022
- Pipeline by TherapyX Inc, 2022
- Dormant Products, 2022
- Discontinued Products, 2022
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Advent Therapeutics Inc
- Avecho Biotechnology Ltd
- Bausch Health Companies Inc
- Boehringer Ingelheim International GmbH
- Galephar Pharmaceutical Research Inc
- Ipsen SA
- Lee's Pharmaceutical Holdings Ltd
- Orphanix GmbH
- Ortho Dermatologics Inc
- Promius Pharma LLC
- Sveikatal Inc
- TherapyX Inc
